Business
Virios Therapeutics Announces New Social Media Profiles
Data from Ongoing Phase 2b Fibromyalgia Trial Projected for Mid-2022 ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"\nData from Ongoing Phase 2b Fibromyalgia Trial Projected for Mid-2022\n\n ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today the expansion of the company's social media platforms as well as social media disclosure.\n\nVirios has established a social presence on LinkedIn, Twitter and Facebook, where current and potential investors and other interested persons can connect with the company and receive future updates. The Company plans to use the newly established social media profiles in addition to the Company’s existing Investor Relations website for the distribution of Company information. Accordingly, investors should connect with Virios to monitor these channels, along with following press releases, SEC filings and public conference calls and webcasts. The links can be found below to each of these platforms.\n\nContent will include company news and updates as well as educational, scientific-based posts regarding Herpes Simplex Virus-1 (\"HSV-1\"), fibromyalgia, irritable bowel syndrome (\"IBS\"), chronic fatigue syndrome (\"CFS\") and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease.\n\n“With the recent news that all 41 sites involved in our ongoing 460 patient Phase 2b fibromyalgia (\"FM\") trial are now fully activated and enrolling patients, now is the perfect time to expand our digital presence through social media,” said Virios Therapeutics CEO Greg Duncan.\n\nMr. Duncan continued, “The current trial builds on the encouraging results from our previously completed 2a FM clinical study that demonstrated our lead antiviral development candidate, orally administered IMC-1, met its primary endpoint of pain reduction and was statistically tolerated better than placebo. With the new trial underway we are excited to share new results and updates with investors and patients alike through these platforms.”\n\nVirios Therapeutics LinkedIn: https://www.linkedin.com/company/ViriosBiotech/\n\nVirios Therapeutics Twitter: https://twitter.com/ViriosBiotech\n\nVirios Therapeutics Facebook: https://www.facebook.com/ViriosBiotech/\n\nAbout Virios Therapeutics \n\nVirios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotec...